Commentary|Videos|August 8, 2024

Building Patient-centric Technology

In part 2 of this video interview, Vincent Keunen, founder & CEO of Andaman7 highlights how technology vendors should be keeping the patient in mind when building solutions.

ACT: What do technology vendors need to focus on most when creating patient-centric solutions?

Keunen: It seems obvious, but ask the patients. Many don't ask the patients. They think they know or they say, “Well, I'm kind of a patient too, so I kind of know what I need, right?” You have to talk to different types of patients, and patients with a serious condition, patients without a serious condition, but a chronic disease maybe that is also difficult to manage in the long term, so really ask the patient. It takes time. It's an effort, and you will get many different points of view. It's hard to reconcile all of them, but it's always the same when you build software—you always have that tension between the various needs and the various points of views of the users, and then trying to find something that is very good for everybody. It’s a real challenge. Usually, patients want to manage their health information. They want to be in control. They have the right to that normally in many countries, and what they want is having the right information at the right time, which seems easy to say, but in practice, there's lots of interoperability issues, exchange of information, privacy, cyber-security issues—there's a lot. Also, the patients don't want their data to be abused, right? That's really the fine line, because when you ask patients if they want to contribute to research, 85% say yes, but if I'm being asked my consent first, if I can remove the consent anytime, if I know who will use the data and for what purpose. There's a number of conditions, but if those conditions are met, then the patients agree to contribute, but then it must be easy to use, as I was saying earlier.


Related to this article

© C Davids/peopleimages.com - © C Davids/peopleimages.com - stock.adobe.com
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Why Seizure Counts Alone Can't Define Success in Epilepsy Trials
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
What It Actually Means to Embed the Patient Voice in Trial Design
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why genuine patient partnership begins before the protocol is written—and what it looks like when patients and caregivers tell you a trial was designed with them in mind.